OCTREOTIDE ACETATE OMEGA 200 MCG
OCTREOTIDE (OCTREOTIDE ACETATE) : 200 MCG · DIN 02248642 · OMEGA LABORATORIES LIMITED
Health Canada status: MARKETED
What is OCTREOTIDE ACETATE OMEGA?
OCTREOTIDE ACETATE OMEGA 200 MCG contains OCTREOTIDE (OCTREOTIDE ACETATE) : 200 MCG. It is listed in the Health Canada Drug Product Database under DIN 02248642, held by OMEGA LABORATORIES LIMITED, supplied as SOLUTION for SUBCUTANEOUS ; INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 11-Mar-2004. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is OCTREOTIDE ACETATE OMEGA used for?
Control of symptoms in metastatic carcinoid, VIPomas, and acromegaly; prevention of complications following pancreatic surgery; emergency management of bleeding gastro-oesophageal varices.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02248642 |
|---|---|
| Brand name | OCTREOTIDE ACETATE OMEGA |
| Generic / active ingredient | OCTREOTIDE (OCTREOTIDE ACETATE) : 200 MCG |
| Manufacturer | OMEGA LABORATORIES LIMITED |
| Strength | 200 MCG |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS ; INTRAVENOUS |
| Schedule | Prescription |
| ATC code | H01CB02 OCTREOTIDE |
| AHFS class | 92:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Mar-2004 |
| Original market date | 2004-03-11 00:00:00 |
How is it administered?
SC (recommended) or IV. Initial: 50 mcg once/twice daily. Maintenance varies by indication (e.g., 100-600 mcg/day for Carcinoid). IV infusion: 25 mcg/hour for 48-120 hours for variceal bleeding.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Diluted solution in physiological saline is stable for 24 hours when stored at room temperature. (Note: Specific refrigerated storage for vials not explicitly in text).
How is it supplied?
Single dose 2-mL vials (50, 100, or 500 mcg/mL) in boxes of 5. Multidose 5-mL vials (200 mcg/mL) in boxes of 1.
Contraindications
Hypersensitivity to this drug or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container.
Warnings and precautions
May cause hypoglycemia/hyperglycemia, hypothyroidism, and gallbladder stones (cholelithiasis). Monitor GH/IGF-1, thyroid function, and gallbladder via ultrasound every 6 months.
Is OCTREOTIDE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by OMEGA LABORATORIES LIMITED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code H01CB02 OCTREOTIDE. 9 of 33 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| OCTREOTIDE ACETATE OMEGA | 100 MCG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02248640 |
| OCTREOTIDE ACETATE OMEGA | 50 MCG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02248639 |
| OCTREOTIDE ACETATE OMEGA | 500 MCG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02248641 |
| OCTREOTIDE INJECTION | 100 MCG | SOLUTION | STERIMAX INC | MARKETED | DIN 02560240 |
| OCTREOTIDE INJECTION | 200 MCG | SOLUTION | STERIMAX INC | MARKETED | DIN 02560283 |
| OCTREOTIDE INJECTION | 500 MCG | SOLUTION | STERIMAX INC | MARKETED | DIN 02560291 |
| SANDOSTATIN | 50 MCG | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 00839191 |
| SANDOSTATIN LAR | 30 MG | Powder For Suspension, Sustained-Release | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02239325 |
| OCPHYL | 100 MCG | SOLUTION | PENDOPHARM DIVISION OF PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02413205 |
| OCPHYL | 50 MCG | SOLUTION | PENDOPHARM DIVISION OF PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02413191 |
Who else supplies OCTREOTIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. OCTREOTIDE appears in 173 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.